Wolverine Trading
APLS

Wolverine Trading’s Apellis Pharmaceuticals APLS Stock Holding History

Wolverine Trading’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.35M Buy
59,400
+30,100
+103% +$702K ﹤0.01% 2586
2025
Q2 		$511K Buy
29,300
+2,800
+11% +$51.8K ﹤0.01% 2932
2025
Q1 		$643K Buy
26,500
+5,200
+24% +$144K ﹤0.01% 2693
2024
Q4 		$679K Sell
21,300
-10,000
-32% -$301K ﹤0.01% 3058
2024
Q3 		$922K Buy
31,300
+9,500
+44% +$352K ﹤0.01% 2431
2024
Q2 		$836K Sell
21,800
-3,600
-14% -$163K ﹤0.01% 2364
2024
Q1 		$1.49M Sell
25,400
-5,300
-17% -$338K ﹤0.01% 1843
2023
Q4 		$1.84M Sell
30,700
-10,400
-25% -$528K ﹤0.01% 1777
2023
Q3 		$1.56M Buy
41,100
+4,900
+14% +$215K ﹤0.01% 1764
2023
Q2 		$3.23M Buy
36,200
+18,600
+106% +$1.6M ﹤0.01% 1189
2023
Q1 		$1.16M Buy
+17,600
New +$1.02M ﹤0.01% 1777
2022
Q2 		– Sell
-35,400
Closed -$1.75M – 4437
2022
Q1 		$1.75M Buy
+35,400
New +$1.56M ﹤0.01% 1884
2021
Q4 		– Sell
-68,400
Closed -$2.32M – 5723
2021
Q3 		$2.32M Buy
+68,400
New +$3.84M ﹤0.01% 1998

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wolverine Trading's APLS Position: Q3 2025 in Review

Wolverine Trading reduced its Apellis Pharmaceuticals (APLS) stake by 11% in Q3 2025, selling an estimated $40.1K and leaving 14,480 shares worth $328K. The position accounts for ﹤0.01% of the portfolio, ranked #4254.

Wolverine Trading first reported a position in APLS in Q3 2021 and has held it in 11 quarters since. The position peaked at $1.13M in Q3 2021. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Wolverine Trading held 14,480 shares of Apellis Pharmaceuticals worth $328K as of Q3 2025.
  • Wolverine Trading sold 1,718 Apellis Pharmaceuticals shares in Q3 2025, an estimated $40.1K.
  • Apellis Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #4254 holding.
  • Wolverine Trading first reported a position in Apellis Pharmaceuticals in Q3 2021 and has held it in 11 quarters since.
  • Wolverine Trading's Apellis Pharmaceuticals position peaked at $1.13M in Q3 2021.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.